8.25

1.20% -0.10

Kyverna Therapeutics Inc (KYTX)

Overview News Price History Discussions Forecast

Kyverna Therapeutics Inc stock is traded at $8.25, with a volume of 499.07K. It is down -1.20% in the last 24 hours and up +6.04% over the past month. Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Previous Close:

$8.35

Open:

$8.26

24h Volume:

499.07K

Relative Volume:

0.50

Market Cap:

$510.21M

Revenue:

Net Income/Loss:

$-156.40M

P/E Ratio:

-2.5153

EPS:

-3.2799

Net Cash Flow:

$-151.53M

1W Performance:

-1.43%

1M Performance:

+6.04%

6M Performance:

-6.99%

1Y Performance:

+127.27%

1-Day Range:

$8.20

$8.38

1-Week Range:

$7.6001

$8.78

52-Week Range:

$3.60

$13.67

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Name

Kyverna Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(510) 626-8331

Address

5980 HORTON STREET, EMERYVILLE

Employee

129

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

KYTX's Discussions on Twitter

Compare KYTX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KYTX Kyverna Therapeutics Inc	8.25	502.79M	0	-156.40M	-151.53M	-3.2799
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-25	Initiated	William Blair	Outperform
May-27-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-10-24	Initiated	UBS	Buy
Oct-09-24	Initiated	Rodman & Renshaw	Buy
Jul-03-24	Initiated	H.C. Wainwright	Neutral
Mar-04-24	Initiated	JP Morgan	Overweight
Mar-04-24	Initiated	Leerink Partners	Outperform
Mar-04-24	Initiated	Morgan Stanley	Overweight
Mar-04-24	Initiated	Wells Fargo	Overweight

View All

Kyverna Therapeutics Inc Stock (KYTX) Latest News

Aug 20, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 7.3%Time to Sell? - MarketBeat

Aug 20, 2026

Miv-cel Earns RMAT Designation for Progressive Multiple Sclerosis - CGTLive®

Aug 20, 2026

Aug 18, 2026

Kyverna (KYTX) Latest Reading: Declines 5.03% to $8.50 in the Latest Session; Session Range View: the Session Ends Within the Reported Technical Boundaries in the Available RecordDay Trade Opportunities - vinanet.vn

Aug 18, 2026

KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits

Aug 18, 2026

Aug 17, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Trading 6.7% HigherShould You Buy? - MarketBeat

Aug 17, 2026

AIGH Capital Management LLC Purchases Shares of 2,795,797 Kyverna Therapeutics, Inc. $KYTX - MarketBeat

Aug 17, 2026

Aug 15, 2026

Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX - MarketBeat

Aug 15, 2026

Aug 14, 2026

KYTX Edges Higher: Kyverna Therapeutics Climbs 1.11% to $8.17Fibonacci Retracement - Vinanet

Aug 14, 2026

Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst - MarketBeat

Aug 14, 2026

Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake - Stock Titan

Aug 14, 2026

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 14, 2026

Aug 13, 2026

KYTX Q1 2026 Earnings: Narrower-than-Expected Loss of -0.66 per Share Highlights Clinical-Stage Cost Discipline - vinanet.vn

Aug 13, 2026

Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX) - Seeking Alpha

Aug 13, 2026

Aug 12, 2026

H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Aug 12, 2026

Kyverna Therapeutics (KYTX) Earnings Date and Reports 2026 $KYTX - MarketBeat

Aug 12, 2026

Aug 11, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Aug 11, 2026

Kyverna Therapeutics narrows Q2 losses, secures RMAT for miv-cel - scanx.trade

Aug 11, 2026

Kyverna Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 11, 2026

Kyverna Therapeutics Announces Q2 2026 Financial Results and Operational Update - Kalkine Media

Aug 11, 2026

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results - The Manila Times

Aug 11, 2026

KYTX: Q2 2026 net loss narrowed to $38.3M as miv-cel advanced toward commercialization - TradingView

Aug 11, 2026

Kyverna Therapeutics (KYTX) deepens pipeline with SPS BLA, H1 2026 loss narrows - Stock Titan

Aug 11, 2026

Aug 09, 2026

Renaissance Technologies LLC Grows Stock Holdings in Kyverna Therapeutics, Inc. $KYTX - MarketBeat

Aug 09, 2026

Aug 07, 2026

Kyverna Therapeutics, Inc. expected to post a loss of 68 cents a shareEarnings Preview - TradingView

Aug 07, 2026